MARKET

VCYT

VCYT

Veracyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

50.90
-0.98
-1.89%
After Hours: 50.90 0 0.00% 16:07 11/25 EST
OPEN
51.71
PREV CLOSE
51.88
HIGH
51.75
LOW
49.39
VOLUME
387.85K
TURNOVER
--
52 WEEK HIGH
53.10
52 WEEK LOW
13.90
MARKET CAP
2.95B
P/E (TTM)
-74.6444
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 1d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 2d ago
Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Business Wire · 2d ago
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 19)
Benzinga · 6d ago
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 11/17 13:31
Veracyte Announces New General Manager Structure to Advance Global Expansion
Veracyte Announces New General Manager Structure to Advance Global Expansion
Business Wire · 11/17 13:30
What We Know About How Moderna and Pfizer Vaccines Compare
“Efficacy is likely the same,” Raymond James analyst Steven Seedhouse surmises. A surer comparison will become possible when both trials report detailed results in medical journals.
Barrons.com · 11/16 20:19
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VCYT. Analyze the recent business situations of Veracyte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VCYT stock price target is 39.40 with a high estimate of 42.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 304
Institutional Holdings: 71.46M
% Owned: 123.42%
Shares Outstanding: 57.90M
TypeInstitutionsShares
Increased
75
9.88M
New
47
-2.44M
Decreased
47
1.72M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Chief Executive Officer/Director
Bonnie Anderson
Chief Financial Officer/Chief Operating Officer
Keith Kennedy
Chief Accounting Officer
Mark Ho
Executive Vice President/General Counsel/Secretary
James Erlinger
Chief Scientific Officer
Giulia Kennedy
Other
John Hanna
Independent Director
Fred Cohen
Lead Director/Independent Director
John Bishop
Director
Jens Holstein
Independent Director
Frederick Cohen
Independent Director
Karin Eastham
Independent Director
Robert Epstein
Independent Director
Kevin Gordon
Independent Director
Evan Jones
Independent Director
Tina Nova
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VCYT
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Veracyte Inc stock information, including NASDAQ:VCYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCYT stock methods without spending real money on the virtual paper trading platform.